Estefanía P. Juliá

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

Estefanía P. Juliá, Analía Amante, M. Betina Pampena et al. · Frontiers in Immunology · 2018 · 123 citations · Full text

Breast Oncology, Immunology, Nk Cells +19

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15

Yamila Rocca, María Paula Roberti, Estefanía P. Juliá et al. · Frontiers in Immunology · 2016 · 92 citations · Full text

Immunology, Immune Regulation, Pathology +21

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients

Estefanía P. Juliá, Pablo Mandó, Manglio Rizzo et al. · Cancer Immunology Immunotherapy · 2019 · 51 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +10

Overexpression of CD85j in TNBC patients inhibits Cetuximab‐mediated NK‐cell ADCC but can be restored with CD85j functional blockade

María P. Roberti, Estefanía P. Juliá, Yamila Rocca et al. · European Journal of Immunology · 2015 · 49 citations · Full text

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

Estefanía P. Juliá, José Mordoh, Estrella Mariel Levy · Cells · 2020 · 25 citations · Full text

Breast Oncology, Immunology, Immune Regulation +23